Showing 1501-1510 of 1690 results for "".
- Meta-Analysis Shows Aerobic Exercise After Stroke Correlates With Improved Endurance and Walking Speedhttps://practicalneurology.com/news/meta-analysis-shows-aerobic-exercise-after-stroke-correlates-with-improved-endurance-and-walking-speed/2468993/A meta-analysis published in the Journal of the American Heart Association found that survivors of stroke who completed aerobic exercise programs achieved improvements in endurance and walking ability. Overall, participant
- Studies Aim to Address Differences in Health Care for Dementia for LGBT Communityhttps://practicalneurology.com/news/studies-aim-to-address-differences-in-health-care-for-dementia-for-lgbt-community/2468961/Finding from the Aging With Pride: IDEA study (NCT03550131), presented at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 show that a strong research-community partnership is necessary for th
- Phase 2 Trial of Niflamapimod for Dementia With Lewy Bodies Beginshttps://practicalneurology.com/news/phase-2-trial-of-niflamapimod-for-dementia-with-lewy-bodies-begins-1/2468960/A phase 2 proof-of-concept clinical study, AscenD-LB (NCT04001517) has begun for neflamapimod (EIP Pharma,Cambridge, MA) as a treatment for the cognitive dysfunction associated with dementia with Lewy bodies (DLB). Accounting for appro
- Promising Data Presented for Investigational Oral Treatment for People with Alzheimer’shttps://practicalneurology.com/news/promising-data-presented-for-investigational-oral-treatment-for-people-with-alzheimers/2484840/Once-daily treatment with tazbentetol (SPG302; Spinogenix, Los Angeles, CA) was associated with rapid and sustained improvements in cognitive and functional measures in a study of adults with mild-to-moderate Alzheimer disease (AD), according to topline results presented at the 18th annual Clinic
- Anti-Tau Antibody Etalanetug Shows Reductions in Novel Biomarker of Tau Tangle Pathology in Dominantly Inherited Alzheimer Diseasehttps://practicalneurology.com/news/anti-tau-antibody-etalanetug-shows-reductions-in-novel-biomarker-of-tau-tangle-pathology-in-dominantly-inherited-alzheimer-disease/2484712/Treatment with the investigational anti-tau antibody etalanetug (E2814; Eisai, Tokyo, Japan) for individuals with dominantly inherited Alzheimer disease (DIAD) was associated with reductions in eMTBR-tau243, a novel cerebrospinal fluid (CSF) biomarker that reflects tau tangle pathology and consis
- Intrathecal Gene Therapy Approved for Adults, Older Children with Spinal Muscular Atrophyhttps://practicalneurology.com/news/intrathecal-gene-therapy-approved-for-adults-older-children-with-spinal-muscular-atrophy/2484610/The Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve; Novartis, Basel, Switzerland) for the treatment of people aged 2 years and older with spinal muscular atrophy (SMA) and a confirmed survival motor neuron 1 (SMN1) gene mutation. The adeno-associated vir
- Artificial Sweeteners Linked to Faster Cognitive Decline in Midlife Adultshttps://practicalneurology.com/news/artificial-sweeteners-linked-to-faster-cognitive-decline-in-midlife-adults/2484026/Higher consumption of low- and no-calorie sweeteners (LNCSs) was associated with accelerated cognitive decline, particularly in verbal fluency and global cognition, among adults aged <60 years. This finding from a longitudinal study published in Neurology contributes to a growing body
- Lower Amyloid Levels after Donanemab Treatment Correlated with Slower Clinical Declinehttps://practicalneurology.com/news/lower-amyloid-levels-after-donanemab-treatment-correlated-with-slower-clinical-decline/2484005/A secondary analysis of results from the TRAILBLAZER-ALZ 2 phase 3 trial (NCT04437511) published in JAMA Neurology demonstrated an association between lower posttreatment amyloid plaque levels and slower cognitive and functional decline in individuals with early Alzheimer disease (AD) tr
- Gene Therapy for Rett Syndrome Receives FDA Breakthrough Therapy Designationhttps://practicalneurology.com/news/gene-therapy-for-rett-syndrome-granted-fda-breakthrough-therapy-designation/2483962/The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102 (Taysha Gene Therapies, Dallas, TX) for the treatment of individuals with Rett syndrome. TSHA-102 is an intrathecally delivered adeno-associated virus 9 (AAV9) gene transfer therapy designed to mediate
- Long COVID “Brain Fog” May Be Linked to an Underlying Molecular Mechanismhttps://practicalneurology.com/news/long-covid-brain-fog-may-be-linked-to-an-underlying-molecular-mechanism/2483959/Cognitive impairment associated with the reported chronic condition often referred to as “long COVID” may be linked to an underlying molecular mechanism characterized by increased α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor density across the brain according to new findi